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radiotherapy patients. Simple radiation protection models 
should be used only with extreme care for risk estimates in 
radiotherapy, since they are developed exclusively for low 
dose. When applied to scatter radiation, such models can 
predict only a fraction of observed second malignancies. 
Better semi-empirical models include the effect of dose 
fractionation and represent the dose-response relationships 
more accurately. The involved uncertainties are still huge for 
most organs and tissues. A major reason for this is that the 
underlying processes of the induction of carcinoma and 
sarcoma are not well known. Most uncertainties are related 
to the time patterns of cancer induction, the population 
specific dependencies and to the organ specific cancer 
induction rates. For radiotherapy treatment plan 
optimization these factors are irrelevant, as a treatment plan 
comparison is performed for a patient of specific age, sex, 
etc. If a treatment plan is compared relative to another one 
only the shape of the dose-response curve (the so called risk-
equivalent dose) is of importance and errors can be 
minimized. One of the largest remaining uncertainties is the 
precision of the dose distribution which is the basic input into 
all risk-estimate-models. Dose calculation and/or 
measurement are as precise as approximately 5% in the 
treated volume of the patient. However, in the periphery 
dose errors can reach 100% and more. The use of erroneous 
dose data (see Figure 1) can lead to wrong risk estimates. 
Therefore a lot of effort is undertaken to produce precise 
dose computations in the whole patient volume about which 
is reported. Strategies are discussed how to include relevant 
dose information into cancer registries. 
Figure 1. Two dose comparisons of the same radiation 
treatment techniques which were used for risk estimates. 
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The association between radiation exposure and cancer risk 
has been studied for several decades, although in the clinical 
oncology setting, significant gaps in the understanding and 
management of radiation therapy (RT) related second cancer 
risks still exist. 
This talk will address the clinical implications of current 
knowledge relating to treatment- related second cancers, 
including:  
1. Treatment selection: Some clinicians or patients may opt 
to avoid RT in order to reduce the risk of second cancers. 
These decisions often reveal important misunderstandings 
about the impact of age, competing risks of death or other 
morbidity, and differences between absolute and relative 
risks. Through a case-based approach, participants will learn 
to identify scenarios in which over- or under-estimation of 
second cancer risk may lead to suboptimal treatment 
choices.  
2. Modification of Radiation Treatment: Oncologists are able 
to deliver dose much more precisely than ever before, but it 
remains difficult to decide where to deposit excess dose, or 
if low doses to large volumes are more carcinogenic than high 
doses to small volumes. The emergence of proton therapy 
now adds further complexity to these issues. In this session, 
participants will learn about dose-risk relationships and the 
clinical implications for radiotherapy planning. 
2. Clinical management in follow-up: Survivorship care is of 
growing clinical concern, and management of second cancer 
risk is an important feature of this care. Oncologists will be 
required to have familiarity with guidelines recommending 
specific screening interventions following RT. Participants 
will learn about resources and guidelines for management of 
second cancer risk, and the evidence supporting these 
guidelines will be reviewed. 
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Purpose or Objective: The influence of HPV positivity on 
therapy response in head and neck squamous cell cancers 
(HNSCC) highlights the importance of uniform and robust 
biomarkers for stratification of HNSCC patients. Our previous 
report indicates that p16 is not only a surrogate marker for 
HPV infections but has an active role in modulation of 
radiotherapy response by impairing DNA damage response 
and repair, which is a process known to be dominant in the 
nucleus of the cells. Based on this, we hypothesized that p16 
compartmentalization according to nuclear and cytoplasmic 
expression may have a role in risk stratification. 
 
Material and Methods: p16 expression (immunostaining) and 
HPV status (GP5+/6+ PCR) was assessed in 241 pretreatment 
biopsies of oropharyngeal cancer patients treated with 
chemoradiotherapy. Tumors were classified in nuclear p16 
expressing (>10% of tumor cells), cytoplasmic (>10% tumor 
cells) and p16 negative groups. Statistical analysis was 
performed to assess the correlation between clinical and 
tumor characteristics and p16 immunostaining. Influence of 
p16 localization on radiotherapy response was further 
assessed by clonogenic and cell survival assays in HPV/p16 
negative HNSCC cells transfected with viral construct 
containing p16-NLS (nuclear localization signal); p16-NES 
(nuclear exit signal) and p16-WT. The expression and 
localization of p16 was confirmed by western blotting and 
immunofluorescence. The response of p16 localization on 
DNA damage response and homologous recombination repair 
(HRR) was assessed by gH2AX, RAD51 foci formation and 
immunoprecipitation. 
 
Results: Nuclear p16 expressing HNSCC showed significant 
(p<0.05) better locoregional control rates (5-year 82%) 
compared to cytoplasmic p16 positive (5-year 55%) and p16 
negative patients (5-year 48%). Only nuclear p16 expression 
was a significant prognostic factor for locoregional control 
with a hazard ratio of 0.48 (p<0.05; 95% CI: 0.22-1.01). 
Interestingly, HPV positive patients were significantly 
enriched in the nuclear p16 expressing group (60%) compared 
to cytoplasmic p16 expressing group (9%). In concordance 
with our patient data, cells containing nuclear p16 expression 
(p16-NLS) showed a higher radiosensitization compared to 
cells with predominant cytoplasmic p16 expression (p16-NES) 
ESTRO 35 2016                                                                                                                                                    S205 
______________________________________________________________________________________________________ 
or p16 negative cells, indicating a differential role of p16 
protein expression depending on its localization. Strikingly, 
cells expressing nuclear p16 (p16-NLS) -although showing a 
similar level of gH2AX induction- were characterized with 
lower number RAD51 foci formation compared to cells 
expressing cytoplasmic p16 (p16-NES), suggesting an impaired 
HRR. 
 
Conclusion: Cellular p16 localization is an important factor 
for stratification of HNSCC patients with nuclear p16 
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Purpose or Objective: To retrospectively assess the 
prognostic value of the potential biomarkers, i.e. chemokine 
receptor CXCR4, its ligand CXCL12 (SDF1), and nuclear EGFR 
expression in a cohort of 201 patients with locally advanced 
HNSCC. Patients were treated between 2005 and 2011 in 8 
German cancer centers, as part of a multicenter biomarker 
study of the German Cancer Consortium Radiation Oncology 
Group (DKTK-ROG). Experimental data and first clinical 
observations suggest that activation of CXCR4 and SDF1 
signaling pathway and nuclear location of EGFR are 
implicated in tumour cell proliferation, cellular survival, 
tumour progression, worse overall survival, metastasis and 
enhanced treatment resistance in different tumour types. 
 
Material and Methods: Patients with locally advanced SCC of 
the oral cavity, oropharynx and hypopharynx were treated 
with resection and adjuvant RT and Cisplatin-based CT. 
Tissue micro-arrays (TMAs) were generated from surgical 
specimens and evaluated for the expression of the 
biomarkers by immunofluorescence with a semi-quantative 
method, based on their cellular location (membranous, 
intracellular, nuclear), extent of expression on TMA area and 
staining intensity. The results of the biomarker analysis along 
with the clinical parameters were then correlated with the 
clinical outcome. 
 
Results: In univariate analysis, tumours with either SDF1 or 
CXCR4 intracellular overexpression displayed a significant 
negative correlation with loco-regional control (LCR) (HR: 
2.52, p=0.01 and HR: 1.96, p=0.05 respectively). No 
correlation was observed for the nuclear expression of EGFR 
(HR: 0.85, p= 0.67), membranous expression of SDF1 (p=0.73) 
or CXCR4 (p=0.38). Tumours with intracellular co-expression 
of both SDF1 and CXCR4 were significantly correlated with 
poor LRC (HR: 2.72, p=0.01). Previously published data from 
the same cohort, showed that absence of p16 (negative HPV 
status) was correlating with poor LRC. Importantly, increased 
expression of SDF1 or co-expression with CXCR4 could 
identify a group of patients with significantly worse outcome 
within the HPV negative group (p=0.01). Multivariate cox 
regression analysis including HPV status, tumour localisation, 
tumour volume and the respective biomarkers indicated a 
significant independent role of SDF1 (HR: 2.20, p=0.04) and 
co-expression with CXCR4 (HR: 2.19, p=0.05) on LRC. 
 
Conclusion: In summary, pre-treatment overexpression of 
CXCR4/SDF1 is an independent negative prognostic factor for 
the outcome of patients with locally advanced HNSCC who 
receive surgery and standard RT-CT. Further investigation in 
a cohort of patient receiving primary RT-CT and a 
prospective validation study is currently ongoing. 
SDF1/CXCR4 appears to be a promising biomarker for 
treatment individualization, in particular in HPV negative 
advanced HNSCC patients and supports strategies using 
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